Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody cocktail aims to stop rabies after multiple dog bites

NCT ID NCT07624461

Prevention Sponsor: Synermore Biologics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a new antibody injection, called zamerovimab and mazorelvimab, combined with the standard rabies vaccine, can prevent rabies in people who have been severely bitten by a dog. The trial follows 80 adults in China for up to one year to see if they stay rabies-free. The goal is to improve protection after high-risk exposures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zamerovimab and mazorelvimab injection (a human rabies antibody cocktail) plus rabies vaccine
What this could lead to
If successful, this could offer a more effective way to prevent rabies after severe dog bites, potentially saving lives in areas where rabies is common.
What could go wrong
This is a small, early real-world study with only 80 participants, so results may not apply to everyone. The treatment might not prevent rabies in all cases, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

People aged 18 or older who were bitten by a dog that also bit others, have a serious (Grade III) rabies exposure, and already received wound cleaning, the antibody injection, and the first rabies shot within 24 hours can join.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged ≥18 years at the time of screening. 2. Sustained a verified WHO Grade III rabies exposure from a traceable offending dog involved in a multi-person canine attack incident (defined as a single animal attacking multiple individuals within a clustered timeframe/location) in Nanyang City. 3. Time interval from Grade III exposure to post-exposure prophylaxis (PEP) initiation is less than 7 days. 4. Successfully completed standard wound debridement, anatomical infiltration of zamerovimab/mazorelvimab injection (0.3 mg/kg single full dose), and the first dose of rabies vaccine within 24 hours prior to screening. 5. Voluntarily provides signed written informed consent. 6. Patient is willing and able to comply with all sequential follow-up procedures (including serum collections if applicable) and intends to reside locally for the full 1-year study duration. Exclusion Criteria: 1. Documented history of any separate animal bite or scratch (e.g., dog, cat, bat, or wild carnivore) within the past 12 months prior to the current exposure. 2. Documented complete pre-exposure or post-exposure rabies vaccination history within the past 12 months. 3. Concurrent presentation with life-threatening traumatic injuries requiring intensive care, or severe systemic immunodeficiency disorders that could impede immunogenicity or follow-up compliance. 4. Any other clinical or psychological condition deemed by the investigator as unsuitable for safe participation or reliable data registry.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rabies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rabies prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rabies Rabies post-exposure prophylaxis

Contacts and locations

Locations

  • The Disease Prevention and Control Center of Nanyang

    Nanyang, Henan, 473000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.